In which countries is Thymosin Alpha-1 approved, and for which indications?

Thymosin Alpha-1 (commercialized as Zadaxin by SciClone Pharmaceuticals) is approved as a pharmaceutical drug in approximately 35 countries, making it one of the more internationally recognized peptide-based immunomodulatory agents. China approved Zadaxin in 1996 for management of chronic hepatitis B, and it subsequently received marketing authorizations across Asia, the Middle East, South America, and parts of Europe. Clinical indications across jurisdictions include chronic hepatitis B, chronic hepatitis C, adjuvant immunotherapy in oncology settings, and immune reconstitution in sepsis. During the COVID-19 pandemic, Thymosin Alpha-1 was used clinically in China under emergency protocols and studied in several investigational trials. It is not FDA-approved for any indication in the United States, where it is used as a compounded research peptide under 503A frameworks. Its extensive multinational approval record represents one of the broadest international regulatory footprints of any injectable research peptide.

What is the mechanism by which Thymosin Alpha-1 modulates T-cell function in research models?

Thymosin Alpha-1 is a 28-amino acid peptide originally derived from thymosin fraction 5 of the thymus gland. Its primary mechanism in preclinical and clinical research involves promotion of T lymphocyte maturation and functional enhancement through multiple complementary pathways. At the receptor level, Thymosin Alpha-1 activates Toll-like receptor 9 (TLR-9) signaling in dendritic cells, stimulating innate immune responses and bridging innate to adaptive immunity. Downstream effects include increased differentiation of CD4+ T-helper and CD8+ cytotoxic T-lymphocytes, enhanced T-cell receptor signaling in immunocompromised states, and upregulation of MHC class I expression on tumor cells — which may contribute to documented anti-tumor immune surveillance effects. In research models of immunocompromised states, Thymosin Alpha-1 has demonstrated the ability to restore T-cell function in subjects with depleted or functionally exhausted T-cell populations, positioning it as a regulatory rather than broadly inflammatory immune modulator.

What does the published safety record show for Thymosin Alpha-1 across clinical trials?

Thymosin Alpha-1 has one of the most favorable published safety profiles among immunomodulatory peptides with substantive clinical trial evidence. A 2024 comprehensive review encompassing more than 30 clinical trials and over 11,000 human research subjects documented a consistent safety profile, with adverse event rates comparable to placebo in controlled trials. No serious dose-limiting toxicities have been identified at pharmacological research concentrations in the clinical literature. The most commonly reported mild adverse events are local reactions at the administration site. Long-term administration in chronic hepatitis B trials extending over multiple years has not identified cumulative toxicity signals. This safety record, combined with demonstrated pharmacological activity in human trials across multiple indications and regulatory jurisdictions, positions Thymosin Alpha-1 as one of the more clinically validated peptides in the immune research category. However, its availability in the United States is limited to compounded preparations absent an FDA-approved formulation.

Thymosin Alpha-1 and Immune Modulation: Research Summary

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide derived from thymosin fraction 5, originally isolated from bovine thymus gland, whose immunomodulatory properties have been studied in the context of viral hepatitis, cancer immunotherapy, sepsis, and more recently COVID-19. This review summarizes published clinical and preclinical research and is intended for scientific reference only — it does not constitute medical advice or therapeutic guidance.

Biochemistry and Origin

Thymosin alpha-1 was first isolated and characterized by Allan Goldstein and colleagues at The George Washington University Medical Center in the 1970s. Goldstein et al. (1977, Proceedings of the National Academy of Sciences) described a family of thymic peptides with immune-enhancing properties, from which the alpha fraction was further fractionated to yield the 28-amino-acid sequence subsequently designated thymosin alpha-1.

The N-terminus of Tα1 is acetylated, which is essential for biological activity — the free N-terminal amine form is substantially less potent in immune assays. The acetyl-Ala N-terminus is a post-translational modification that occurs naturally in thymic tissue.

A synthetic version of Tα1 (trade name Zadaxin, SciClone Pharmaceuticals) has received regulatory approval in Italy and several Asian and Middle Eastern markets for hepatitis B, hepatitis C (in combination with interferon), and as an adjunct in immunocompromised patients. This approval provides a regulatory basis for the compound's safety profile in humans that distinguishes it from most peptides discussed in this database.

See the Thymosin Alpha-1 compound library entry for the full sequence, post-translational modification details, and regulatory approval history.

TLR-9 Signaling and Innate Immune Activation

Thymosin alpha-1's mechanism of action has been characterized through multiple pathways. A key molecular target identified in more recent research is Toll-like receptor 9 (TLR-9), a pattern recognition receptor expressed on plasmacytoid dendritic cells (pDCs) and B cells that recognizes unmethylated CpG DNA motifs.

Romani et al. (2004, Blood) demonstrated that Tα1 potentiated TLR-9 signaling in dendritic cells, promoting the production of Th1-polarizing cytokines including IFN-α, IFN-γ, and IL-12. This TLR-9 interaction provides a molecular framework for Tα1's observed ability to augment antiviral and antitumor immune responses.

Dendritic Cell Maturation

Tα1 has been shown to promote the maturation and activation of dendritic cells (DCs) in multiple experimental systems. Huang et al. (2006, European Journal of Immunology) reported that Tα1-treated monocyte-derived DCs showed increased surface expression of MHC II, CD86, and CD80 maturation markers, enhanced IL-12 production, and superior T cell priming capacity in mixed lymphocyte reactions.

This DC-maturing activity is proposed as a primary mechanism by which Tα1 enhances adaptive immune responses — by improving the efficiency of antigen presentation and costimulation required for T cell activation.

T-Cell Differentiation and Adaptive Immunity

Consistent with thymosin's origin as a thymic hormone, Tα1 has been associated with T-cell maturation and differentiation in both preclinical and clinical contexts.

Ershler et al. (1985, International Journal of Immunopharmacology) reported that Tα1 treatment augmented T-cell responsiveness in elderly individuals with age-associated immune decline, including restoration of mitogen-stimulated lymphocyte proliferation. This age-related immune restoration framing has recurred across the Tα1 literature.

Garaci et al. (multiple publications, 1994–2010, Archives of Internal Medicine and Journal of Immunology) produced a substantial body of work characterizing Tα1's effects on CD4+/CD8+ T cell subset balance, NK cell activity, and cytokine profiles in immunocompromised patients, primarily in the context of HIV and HCV co-infection.

Hepatitis B and C Clinical Trials

Hepatitis B

Multiple clinical trials have examined Tα1 for chronic hepatitis B (CHB) infection, primarily in Asian populations with high disease burden. Chien et al. (1998, Hepatology) conducted a randomized controlled trial of Tα1 monotherapy in CHB, reporting significantly higher seroconversion rates from HBeAg-positive to HBeAg-negative status in treated patients at 12 months compared to placebo controls.

A meta-analysis by You et al. (2006, World Journal of Gastroenterology) synthesized data from multiple CHB trials and reported that Tα1 significantly improved HBV DNA suppression and normalized alanine aminotransferase (ALT) levels compared to controls, with a favorable safety profile.

Hepatitis C

The Italian regulatory approval of Zadaxin for hepatitis C is based substantially on combination therapy studies with interferon-alpha. Rasi et al. (1996, Hepatology) reported a controlled trial demonstrating superior sustained virological response rates when Tα1 was added to interferon-alpha therapy compared to interferon alone in genotype 1 HCV patients — a difficult-to-treat population.

The Italian experience with Tα1 in HCV, accumulated across the 1990s–2000s, represents the most robust clinical dataset outside of oncology for this compound.

Cancer Immunotherapy Studies

Tα1 has been investigated as an immunoadjuvant in multiple cancer settings, primarily exploiting its DC-activating and Th1-polarizing properties.

Garaci et al. (1995, Archives of Internal Medicine) published results of a trial in non-small cell lung cancer (NSCLC) patients receiving Tα1 in combination with chemotherapy, reporting improved immune function markers and a trend toward prolonged survival in the treated group compared to chemotherapy alone.

A meta-analysis of Tα1 in non-small cell lung cancer by Li et al. (2015, PLOS ONE) synthesized data from multiple Chinese randomized trials and reported significantly improved overall survival and immune parameters in Tα1-treated groups. The authors acknowledged limitations including trial quality heterogeneity and predominantly single-center designs.

COVID-19 Research: Italian ICU Studies

One of the most acute periods of interest in Tα1 came during the COVID-19 pandemic, when the compound's immunomodulatory profile was hypothesized to address the pathological immune dysfunction — including lymphopenia, NK cell exhaustion, and DC dysfunction — characteristic of severe COVID-19.

Morán Garcia et al. and the Italian intensive care community published observations on Tα1 use in severe COVID-19 patients, but the most systematic early data came from Liu et al. (2020, Clinical Infectious Diseases), reporting that Tα1 administration to moderate-to-severe COVID-19 patients in China was associated with reduced 28-day mortality compared to standard care alone, primarily in elderly patients.

Shi et al. (2020, Signal Transduction and Targeted Therapy) provided a mechanistic analysis proposing that Tα1's ability to restore T-cell function and reduce pathological IL-6 levels could address multiple arms of COVID-19 immune pathology simultaneously.

These COVID-19 studies are retrospective or small prospective analyses; randomized controlled trial data specifically for COVID-19 with Tα1 remains limited.

Safety Profile

The clinical safety record of Tα1 across hepatitis and oncology trials is generally favorable. Common adverse effects reported across trials include mild injection site reactions and infrequent, transient flu-like symptoms. No serious immunological adverse events such as autoimmunity induction have been reported across decades of clinical use, consistent with Tα1's mechanism as an immunomodulator that amplifies normal immune responses rather than producing non-physiological immune activation.

The Italian regulatory approval of Zadaxin, sustained over multiple decades, reflects an accumulated safety database that distinguishes Tα1 from most peptide research compounds.

All content on ClinicalPeptide.org is provided for research and educational reference only. Regulatory approval of a compound in specific jurisdictions does not constitute a recommendation for its use; researchers should consult current regulatory guidance in their jurisdiction. Nothing on this site constitutes medical advice.